Contact

Adam J.N. Raymakers, PhD

Our Team

Adam J.N. Raymakers, PhD

Postdoctoral Research Fellow

Adam Raymakers is a Postdoctoral Research Fellow with PORTAL. His research interests include cell and gene therapies in rare and ultra-rare diseases, methods of economic evaluation, the intersection of climate change and healthcare, and health technology assessment. He is a member of the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) at Canada’s Drug Agency and serves on the editorial boards of the Journal of Cancer Policy and Applied Health Economics and Health Policy.

Raymakers completed his PhD in health economics and pharmacoepidemiology at the University of British Columbia. He has held postdoctoral fellowships at the Health Economics and Policy Analysis Centre at the University of Galway, where he focused on the economic evaluation of medical devices, and jointly at BC Cancer and Simon Fraser University, where he studied the economic evaluation of cell and gene therapies in cancer and was awarded a Michael Smith Health Research British Columbia postdoctoral award.

Featured Work

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

An Empirical Investigation Into Concerns Over Quality-Adjusted Life-Years: A Review of Cost-Effectiveness Analyses in Oncology

Raymakers AJN, Rand LZG, Feldman WB, Kesselheim AS - Journal of Cancer Policy

Research Publications

| March 2025

Price, Value, and Access

A common argument put forth by those who wish to restrict the use of quality-adjusted life-years (QALYs) is that cost-effectiveness analyses (CEAs) using QALYs identify sub-groups of patients for whom a new treatment is not considered cost-effective, thereby limiting access. In this analysis, the authors identified all US-based cancer CEAs and found no substantive evidence that this analytical framework was used in the way suggested. These findings are further evidence that bans on QALY use lack empirical justification.

View Source

Inhaler-Related Greenhouse Gas Emissions in the US: A Serial Cross-Sectional Analysis

Feldman WB, Han J, Raymakers AJN, Furie GL, Chesebro BB - JAMA

Research Publications

| November 2025

Regulation and Clinical Evidence

Between 2014 and 2024, the greenhouse gas emissions of asthma and COPD metered-dose inhalers in the US accounted for 98% of the estimated 24.9 million metric tons of CO₂-equivalent emissions during this period, equivalent to 530,000 gas-powered cars on the road each year. Policymakers and regulators should incentivize a shift toward dry powder and soft mist inhalers while facilitating market entry of affordable low-emission metered-dose products.

View Source

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

Raymakers AJN, Kesselheim AS, Mostaghimi A, Feldman WB - JAMA Dermatology

Research Publications

| March 2024

Price, Value, and Access

Beremagene geperpavec (B-VEC) is a topical gene therapy FDA-approved in 2023 for both recessive and dominant dystrophic epidermolysis bullosa (DEB). US spending on B-VEC therapy was estimated to reach $805 million in the first three years post-approval, with a lifetime cost of $15 and $17 million per patient with recessive or dominant DEB, respectively.

View Source